StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.41 | $0.42 | +1.40% | 0.7M |
| 05-12 | $0.43 | $0.35 | -19.46% | 0.7M |
| 05-13 | $0.35 | $0.34 | -1.76% | 0.7M |
| 05-14 | $0.34 | $0.39 | +15.62% | 0.9M |
| 05-15 | $0.39 | $0.44 | +11.90% | 0.8M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $456.02K | $361.66K | $277.42K | $109.31K |
Operating Income | $-18.03M | $-17.66M | $-10.12M | $-4.85M |
Net Income | $-20.64M | $-17.87M | $-10.26M | $-4.84M |
EPS (Diluted) | $-2.17 | $-2.16 | $-1.60 | $-1.29 |
Total Assets | $16.09M | $16.53M | $20.84M | $21.75M |
Total Liabilities | $890.57K | $804.27K | $1.60M | $1.50M |
Cash & Equivalents | $1.49M | $481.28K | $101.02K | $76.50K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 15.89M | 13.88M | 10.64M | 7.14M |
No sell-side coverage available for MGRX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.